Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

María Matellanes-Palacios

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Dermatology Online Journal|September 17, 2020
Giant pilomatrixoma: a distinctive clinical variant: a new case and review of the literatureJavier Sabater-Abad, María Matellanes-Palacios, Laia Bou-Boluda, et al.
Dermatologic Therapy|April 4, 2020
Efficacy and safety of adalimumab 80 mg in the treatment of psoriasis: a bicentric retrospective studyJavier Sabater-Abad, María Matellanes-Palacios, Laia Bou-Boluda, et al.
Dermatology and Therapy|February 24, 2026
Minimal Disease Activity as a Therapeutic Goal in Atopic Dermatitis: Predictive Factors of Sustainability in a Multicenter CohortFrancisco Javier Melgosa Ramos, Santiago Guillén Climent, Marta Galarreta Pascual, et al.
The Australasian Journal of Dermatology|June 19, 2024
Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational studyMiguel Mansilla-Polo, Martí Pons-Benavent, Pablo Fernández-Crehuet, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Dermatology Online Journal|September 17, 2020
Giant pilomatrixoma: a distinctive clinical variant: a new case and review of the literatureJavier Sabater-Abad, María Matellanes-Palacios, Laia Bou-Boluda, et al.
Dermatologic Therapy|April 4, 2020
Efficacy and safety of adalimumab 80 mg in the treatment of psoriasis: a bicentric retrospective studyJavier Sabater-Abad, María Matellanes-Palacios, Laia Bou-Boluda, et al.
Dermatology and Therapy|February 24, 2026
Minimal Disease Activity as a Therapeutic Goal in Atopic Dermatitis: Predictive Factors of Sustainability in a Multicenter CohortFrancisco Javier Melgosa Ramos, Santiago Guillén Climent, Marta Galarreta Pascual, et al.
The Australasian Journal of Dermatology|June 19, 2024
Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational studyMiguel Mansilla-Polo, Martí Pons-Benavent, Pablo Fernández-Crehuet, et al.
Pageof 1